Ibrutinib launched for treatment of mantle cell lymphoma and chronic lymphocytic leukaemia Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been launched in the UK for the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia.…
Medicines regulator amends conflict of interest rules to ensure suitability of experts The European Medicines Agency has amended its policy on handling declarations of interest to ensure pharmaceutical experts are not unduly excluded.…
EllaOne to be available without prescriptionEllaOne (ulipristal acetate), an emergency contraceptive, is to be made available without a prescription from community pharmacies throughout the European Union.…
Pipeline November 2014 The latest approvals and positive opinions from the European Medicines Agency.…
Medicinal cannabis: time for a comeback? The stringent laws on cannabis do no favours for patients, clinicians and researchers.…
Major bleeding risk higher for dabigatran than for warfarin, study suggests Research suggests that dabigatran is associated with a higher risk of bleeding compared with warfarin in a US population sample.…
UK bill aims to allow off-patent drugs to be licensed for new purposes A bill going through Parliament wants the National Institute for Health and Care Excellence (NICE) to appraise off-patent drugs to allow them to be used for new indications.…
UK medicines regulator appoints Michael Rawlins as chairmanThe Medicines and Healthcare products Regulatory Agency has appointed Michael Rawlins as its chairman from 1 December 2014.…
Ensuring medicines safety and managing risk as a Qualified Person for Pharmacovigilance Derek Woodcock is a Qualified Person for Pharmacovigilance and works as a consultant for a variety of pharmaceutical companies. Here, he explains why pharmacovigilance does not have to be seen as the department of “bad news”.…
Smart drugs worth £200,000 seized in the UKA haul of “smart drugs” with a street value of £200,000 has been seized in the UK. …